entertainment -WSS

entertainment

author：hotspot 2025-09-30 10:56:54 - browse：7781

Adam's take main illustration — Molly Ferguson/STAT

Have you heard the news? I’m launching a weekly email newsletter starting on March 28. It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.

In other words, a lot like the content below. I’m really excited to get started and I hope you’ll find the newsletter worthy of your inbox real estate.

This week: A deep dive into the bull and bear sides of the Applied Therapeutics debate, and another well-deserved swipe at Cassava Sciences and its entirely ridiculous Alzheimer’s drug candidate.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Study suggests Covid rebound is far more common with Paxlovid than without

WSS

Resistance to opioid

Juul documents reveal insider tactics on political lobbying

Study gives hint on South Asians’ higher risk of cardiovascular disease

Resistance to opioid

Long Covid research funding gets a major boost from NIH

Study suggests Covid rebound is far more common with Paxlovid than without

Wikipedia

entertainment

leisure time

Guidelines to prevent youth baseball injuries need more muscle

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

A letter from the executive editor: STAT UnitedHealth investigation

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

NIH chief: government has fallen behind pharma on clinical trials

The cancer drug shortage isn’t new — and neither are the solutions

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Novavax promises a turnaround & Lilly roils the obesity market

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

explore

Congress considering partial increase for doctor pay in Medicare

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Congress must protect the remaining independent doctors

Readout Newsletter: Amylyx, Aurinia, and IQVIA

entertainment

focus

knowledge

focus